Another IN vaccine, a live-attenuated vaccine against the respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2 (MV-014-212) is under phase I trial by Meissa Vaccines, Inc. The MV-014-212 is administered as drops or a spray in the nose of healthy adults who are seronegative to SARS-CoV-2 and have not received a prior vaccine against COVID-19 (NCT04798001). This evidence concerns the gene PROS1 and COVID-19.